Clin Exp Pediatr.  2021 Jun;64(6):269-279. 10.3345/cep.2020.02096.

Application of CRISPR-Cas9 gene editing for congenital heart disease

• Seok H
• Deng R
• Cowan DB
• Wang DZ

• KMID: 2516271
• DOI: http://doi.org/10.3345/cep.2020.02096

Abstract

Clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR-Cas9) is an ancient prokaryotic defense system that precisely cuts foreign genomic DNA under the control of a small number of guide RNAs. The CRISPR-Cas9 system facilitates efficient double-stranded DNA cleavage that has been recently adopted for genome editing to create or correct inherited genetic mutations causing disease. Congenital heart disease (CHD) is generally caused by genetic mutations such as base substitutions, deletions, and insertions, which result in diverse developmental defects and remains a leading cause of birth defects. Pediatric CHD patients exhibit a spectrum of cardiac abnormalities such as septal defects, valvular defects, and abnormal chamber development. CHD onset occurs during the prenatal period and often results in early lethality during childhood. Because CRISPR-Cas9-based genome editing technology has gained considerable attention for its potential to prevent and treat diseases, we will review the CRISPR-Cas9 system as a genome editing tool and focus on its therapeutic application for CHD.

Keyword

CRISPR; Genome editing; Congenital heart diseases; Childhood onset